Episodios

  • Diabetic Retinopathy Severity and Income Status

    Diabetic Retinopathy Severity and Income Status
    Jul 18 2025
    Are patients from lower-income households more likely to present with severe diabetic retinopathy (DR)? Ben Young, MD, moderates a discussion with Phoebe Mellen, MD, and Jordan Deaner, MD, about a new retrospective cohort study from the Duke Eye Center than examines differences in DR severity at presentation between patients from the lowest- and highest-income ZIP codes, explores how income-based barriers to care may impact disease progression, and discusses how this data might affect clinical care, screening strategies, and public health priorities.
    Más Menos
    20 m
  • GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates

    GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates
    Jul 7 2025
    How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In part 1 of this 2-part series, moderator Judy Kim, MD, and panelists Sunir Garg, MD; Deepak Sambhara, MD, and Rishi Singh, MD, explore these questions in a brief (but enlightening) discussion.
    Más Menos
    7 m
  • GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy

    GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy
    Jul 7 2025
    What do you do when a patient with GA also has wet AMD? And how do you encourage patients on anti-complement therapy to stick with treatment? In part 2 of this 2-part series, moderator Judy Kim, MD, and panelists Rishi Singh, MD; Deepak Sambhara, MD, and Sunir Garg, MD, examine answers to these questions.
    Más Menos
    11 m
  • Photobiomodulation for Age-related Macular Degeneration

    Photobiomodulation for Age-related Macular Degeneration
    Jun 20 2025
    What conclusions can be drawn from the LIGHTSITE III study examining photobiomodulation for dry AMD? Moderator Barton Blackorby, MD, sits down with panelists Hong-Uyen Hua, MD, and Louis Cai, MD, to examine a recent opinion piece published in JAMA Ophthalmology exploring what researchers can (and cannot) confidently conclude based on the study’s data.
    Más Menos
    19 m
  • Duke AVS Clips: PVR, DR, Imaging, and MTM

    Duke AVS Clips: PVR, DR, Imaging, and MTM
    Jun 12 2025
    Duke faculty interview key lecturers from the 2025 Duke AVS Course about their podium talks. Jason Hsu, MD, discusses the best ways to manage proliferative vitreoretinopathy, Majda Hadziahmetovic, MD, shares new data on the effect of GLP-1 receptor agonists on diabetic retinopathy, Aleksandra V. Rachitskaya, MD, explains the value of multimodal Imaging in adults with a history of prematurity, and Gavin Tan, MD, PhD, FRCSed, discusses management approaches for myopic tractional maculopathy and macular holes.
    Más Menos
    18 m
  • Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI

    Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI
    Jun 9 2025
    Faculty from the 2025 Duke AVS Course ask key lecturers to share pearls from their presentations. Lejla Vajzovic, MD, discusses various pediatric retinal conditions that can manifest later in life, Jason Fan, MD, explains trends in anesthesia use for open-globe surgery, and Glenn J. Jaffe, MD, examines the role of AI in retina clinical trials.
    Más Menos
    12 m
  • Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs

    Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs
    Jun 5 2025
    During the 2025 Duke AVS Course, Duke faculty sat down with several key lecturers to discuss their presentations. Avni P. Finn, MD, MBA, discussed her experiences delivering subretinal gene therapy, David Zacks, MD, PhD, explored important factors in retinal detachment repair, Xi Chen, MD, PhD, highlighted the various surgical approaches for young patients who present without a posterior vitreous detachment, and Yannek I. Leiderman, MD, PhD, provided pearls for scleral fixation of secondary IOLs.
    Más Menos
    17 m
  • ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

    ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data
    May 29 2025
    Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results from the phase 2a BETTER study, which assessed the use of the anti-fibrosis agent ISTH0036 in patients with wet AMD and DME. And Diana Do, MD, sits down to review data from the LIGHTSITE IIIB study, which examined whether patients who underwent photobiomodulation therapy realized any benefit after re-administration following a 13-month washout period. Did the break in treatment lead to irreversible vision loss? Or were patients able experience a benefit after taking more than a year off? We have the answers in this episode.
    Más Menos
    24 m